In the race to find Ozempic 2.0, a few stand-outs are emerging. While GLP-1 drugs have paved the way for a new era of healthcare, they have some drawbacks. They need to be injected (a draw-back ...

GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly, Viking ...

GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

The government says charging for hand luggage and printing boarding passes at the airport are "abusive practices". A British woman helping with recovery efforts in the Spanish city says the ...

New Delhi: Semaglutide, a fat-busting weekly injectable that has been a global smash hit since its launch five years ago, may soon have a successor that promises to be even more effective in shedding ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

U.S. stocks slid Thursday, as Federal Reserve Chair Jerome Powell signaled that the strength of the economy could warrant some patience with future rate cuts. Stocks took a leg lower after Federal ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S ...

On Monday, JPMorgan (NYSE:JPM) maintained a positive outlook on Novo Nordisk (CSE:NOVOb) (NOVOB:DC) (NYSE: NYSE:NVO), reiterating an Overweight rating and a price target of DKK1,050.00. The firm's ...

On Monday, JPMorgan maintained a positive outlook on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), reiterating an Overweight rating and a price target of DKK1,050.00. The firm's analysis ahead of the ...